Junshik Hong1, Hyun Seon Woo1, Hee Kyung Ahn1, Sun Jin Sym1, Jinny Park2, Eun Kyung Cho1, Dong Bok Shin1, Jae Hoon Lee3. 1. Division of Hematology and Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon Regional Cancer Center, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon, 405-760, Republic of Korea. 2. Division of Hematology and Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon Regional Cancer Center, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon, 405-760, Republic of Korea. jhagnes@gilhospital.com. 3. Division of Hematology and Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon Regional Cancer Center, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Namdong-gu, Incheon, 405-760, Republic of Korea. jhlee@gilhospital.com.
Abstract
PURPOSE: The purpose of this study is to evaluate the role of C-reactive protein (CRP) and ferritin blood levels in predicting the incidence of systemic infection among adult patients with acute myeloid leukemia (AML) treated with induction chemotherapy. METHODS: Adult patients with newly diagnosed AML who were initially treated with conventional 3 + 7 induction chemotherapy within 5 days of their diagnosis were included. Patients with previous cytotoxic chemotherapy <3 years, acute promyelocytic leukemia diagnosis, human immunodeficiency virus infection, or significant systemic infection at the time of diagnosis were excluded. Patients were treated with an institutional policy of substantial identity with negligible differences regarding supportive care. RESULTS: Among 110 patients (median age 54.5 years), 39 infectious events in 38 patients were reported, along with 21 episodes of infectious treatment-related mortality (TRM; 19.1%). Elevated pre-treatment CRP (p = 0.032) and ferritin (p = 0.002) were related to the incidence of systemic infection. The degree of increase of blood CRP and ferritin level was correlated with the extent of leukocytosis. However, patients with elevated inflammatory markers above normal range had increased risk of infection irrespective of whether they had leukocytosis or not, suggesting that expansion of leukemic blast is another factor affecting the elevation of the markers independent to infection propensity and therefore the magnitude of the elevation does not quantitatively predict the risk of infection. CONCLUSIONS: Modest elevation of baseline blood inflammatory markers above the normal range could be an indicator for predicting the incidence of systemic infection in patients with AML.
PURPOSE: The purpose of this study is to evaluate the role of C-reactive protein (CRP) and ferritin blood levels in predicting the incidence of systemic infection among adult patients with acute myeloid leukemia (AML) treated with induction chemotherapy. METHODS: Adult patients with newly diagnosed AML who were initially treated with conventional 3 + 7 induction chemotherapy within 5 days of their diagnosis were included. Patients with previous cytotoxic chemotherapy <3 years, acute promyelocytic leukemia diagnosis, human immunodeficiency virus infection, or significant systemic infection at the time of diagnosis were excluded. Patients were treated with an institutional policy of substantial identity with negligible differences regarding supportive care. RESULTS: Among 110 patients (median age 54.5 years), 39 infectious events in 38 patients were reported, along with 21 episodes of infectious treatment-related mortality (TRM; 19.1%). Elevated pre-treatment CRP (p = 0.032) and ferritin (p = 0.002) were related to the incidence of systemic infection. The degree of increase of blood CRP and ferritin level was correlated with the extent of leukocytosis. However, patients with elevated inflammatory markers above normal range had increased risk of infection irrespective of whether they had leukocytosis or not, suggesting that expansion of leukemic blast is another factor affecting the elevation of the markers independent to infection propensity and therefore the magnitude of the elevation does not quantitatively predict the risk of infection. CONCLUSIONS: Modest elevation of baseline blood inflammatory markers above the normal range could be an indicator for predicting the incidence of systemic infection in patients with AML.
Authors: J Kanda; C Mizumoto; T Ichinohe; H Kawabata; T Saito; K Yamashita; T Kondo; S Takakura; S Ichiyama; T Uchiyama; T Ishikawa Journal: Bone Marrow Transplant Date: 2010-05-03 Impact factor: 5.483
Authors: S P Ballou; F B Lozanski; S Hodder; D L Rzewnicki; L C Mion; J D Sipe; A B Ford; I Kushner Journal: Age Ageing Date: 1996-05 Impact factor: 10.668
Authors: Jacob M Rowe; Donna Neuberg; William Friedenberg; John M Bennett; Elisabeth Paietta; Adel Z Makary; Jane L Liesveld; Camille N Abboud; Gordon Dewald; F Ann Hayes; Martin S Tallman; Peter H Wiernik Journal: Blood Date: 2003-09-25 Impact factor: 22.113
Authors: Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245